Viyash Scientific Ltd

Viyash Scientific Employee Stock Options

Viyash Scientific allotted 1,107,309 ESOP shares at exercise prices of ₹86 and ₹101. Paid-up capital rose to ₹88.33 Crore post-allotment.

Viyash Scientific Merger & Restructuring

Viyash Scientific Limited announced receipt of Italian regulatory approval for its subsidiary Alivira Animal Health's acquisition of BioForLife Italia S.r.l. The transaction completion timeline is extended.

Viyash Scientific Acquisition

Viyash Scientific Limited received Italian regulatory approval for its proposed 100% acquisition of BioForLife Italia S.r.l., with the completion timeline now extended by two months.

Viyash Scientific Employee Stock Options

Viyash Scientific Limited allotted 6,12,773 equity shares following the exercise of options under its ESOP 2020 and 2026 schemes. The company's paid-up capital increased to Rs. 88.10 Crore.

Viyash Scientific Promoter Selling

Promoters CA Harbor Investments and CA Hull Investments sold a combined 5.03 crore equity shares of Viyash Scientific Limited through open market transactions.

Viyash Scientific Investor Presentation: Key Takeaways

Viyash Scientific delivered strong Q1 FY27 results with 19.5% revenue growth and significant margin expansion. Integration is complete, and the company is now virtually debt-free, pivoting toward oncology and companion animal health.

Call

Guides 18% growth

Viyash Scientific Earnings Call Transcript: Key Takeaways

Viyash reports a robust Q1FY27 with 20% revenue growth and significantly expanded EBITDA margins at 21.6%. The company is essentially net-debt free following successful integration and is pivoting toward high-potent oncology products.

Call

Guides 18% growth

Viyash Scientific Investor Presentation: Key Takeaways

Viyash Scientific reported strong Q1 FY27 results with 19.5% YoY revenue growth and 59.2% EBITDA growth, driven by integration success and operational leverage.

Viyash Scientific Merger & Restructuring Worth ₹3.82 Cr

Viyash Scientific Ltd is incorporating a new subsidiary, Alivira Vietnam Company Limited, with a cash investment of ₹3.82 Crore. This expands its global subsidiary structure.

Value

₹3.82 Cr

Viyash Scientific Merger & Restructuring Worth ₹400 Cr

Viyash Scientific Limited will convert intercompany loans into equity in its subsidiary, Alivira Animal Health Limited, valued at ₹400.02 Crore. The move strengthens the subsidiary's capital structure.

Value

₹400.0 Cr

Viyash Scientific Annual General Meeting

Viyash Scientific held its 41st Annual General Meeting on August 11, 2026. Shareholders considered and voted on six resolutions, including adoption of financial statements.

Viyash Scientific Results Update

Viyash Scientific reported Q1 FY27 revenue of ₹9,464 million and PAT of ₹793 million. The company announced its financial performance highlights ahead of an upcoming investor call.

Viyash Scientific Q1 FY27 Results: Net Profit ₹79.3 Cr, Up 114.9% YoY

Viyash Scientific Ltd reported revenue from operations of ₹946.4 Cr (+19.6% YoY) and net profit of ₹79.3 Cr (+114.9% YoY) for Q1 FY27.

Key figure

Net profit ₹79.3 Cr · +114.9% YoY

Viyash Scientific Board Meeting Date

Viyash Scientific Limited will hold a board meeting on August 11, 2026, to consider and approve the company's unaudited financial results for the quarter ended June 30, 2026.

Viyash Scientific Employee Stock Options

Viyash Scientific Limited has allotted 20,01,336 equity shares under the SeQuent ESOP 2020 plan. This allotment increases the company's paid-up equity share capital.

Viyash Scientific Merger & Restructuring Worth ₹186.7 Cr

Viyash Scientific Ltd's subsidiary executed a share purchase agreement to acquire BioForLife Italia S.r.l. The transaction is valued at approximately EUR 16.976 million.

Value

₹186.7 Cr

Viyash Scientific Other Announcement

Viyash Scientific Limited provided shareholders with the web-link for the Annual Report 2025-26. The 41st Annual General Meeting is scheduled for August 11, 2026.

Viyash Scientific Business Update

Viyash Scientific Limited submitted its Business Responsibility and Sustainability Report for FY 2025-26. The report details the company's environmental, social, and governance performance metrics.

Viyash Scientific Annual General Meeting

Viyash Scientific Limited scheduled its 41st AGM for August 11, 2026. Shareholders will vote on director re-appointments and adoption of new Articles of Association.

Viyash Scientific Annual Report

Viyash Scientific Limited released its FY 2025-26 Annual Report and 41st AGM notice. The meeting is scheduled for August 11, 2026, via video conferencing.

Viyash Scientific Legal & Regulatory

Viyash Scientific received an SEBI administrative warning for SDD maintenance. No financial or operational impact is reported, per the company's disclosure.

Viyash Scientific Annual General Meeting

Viyash Scientific announced postal ballot results. Shareholders approved the appointments of Amit Jain and Abhiroop Jayanthi as Non-Executive Directors.

Viyash Scientific Business Update

Viyash Scientific shared its Investor Day presentation, outlining its integrated pharmaceutical strategy and leadership profile. No new financial or operational data were disclosed.

Viyash Scientific Earnings Call: Key Takeaways

Viyash Scientific targets a $1Bn revenue platform by 2032 through the merger of Sequent and Viyash Life Sciences, focusing on animal and human health.

Viyash Scientific Acquisition Worth ₹188 Cr

Viyash Scientific acquired 100% of Italy's BioForLife for ₹188 Crore. The strategic move strengthens its European companion animal health presence and global growth footprint.

Value

₹188.0 Cr

Execution

Q2 FY27

Viyash Scientific Acquisition Worth ₹185 Cr

Viyash Scientific acquired 100% of BioForLife Italia for €16.975 million (₹185.03 Crore). The acquisition strengthens the company's companion animal health presence in the Italian market.

Value

₹185.0 Cr

Execution

Initial closing expected within 3 months

Viyash Scientific Annual General Meeting

Viyash Scientific Limited issued a postal ballot notice for director appointments and a one-time incentive. Shareholders will vote on a ₹4.00 Crore performance bonus.

Value

₹4.00 Cr

Viyash Scientific Other Announcement

Viyash Scientific Limited filed its Annual Secretarial Compliance Report for the year ended March 31, 2026. The report details regulatory compliance and historical governance observations.

Viyash Scientific Credit Rating

India Ratings withdrew its rating on Viyash Scientific's ₹35 Crore bank facilities at the company's request. ICRA upgraded its rating to [ICRA] AA- (Stable).

Value

₹35.00 Cr

Viyash Scientific Earnings Call: Key Takeaways

Viyash reports a transformative Q4 FY26 with EBITDA surpassing ₹200cr. Revenue rose 19.1% YoY to ₹920cr, driven by integration synergies and a shift toward high-potent human and animal health products.